The Cleveland Clinic ReCOVer Clinic is enrolling Long COVID patients in the NIH RECOVER-VITAL clinical study. The study will determine whether PAXLOVID, an antiviral drug used to treat mild-to-moderate COVID infections, can be used to treat Long COVID.

It is estimated that 7.5% of adults in the United States experience long COVID after recovering from their initial infection. Symptoms of Long COVID, lasting 28 days or longer after initial infections, include exhaustion, brain fog, dizziness, fast heart rate, shortness of breath, gastrointestinal issues and neurological issues. 

Individual must meet the following criteria to become a ReCOVer clinic patient:

  • Present a positive PCR or at home COVID-19 test indicating infection 
  • Ongoing or new symptoms at least 28 days after being diagnosed with COVID-19. 

The reCOVer Clinic began in February of 2021 and has since seen over 2500 patients.

More information on the RECOVER-VITAL trial is available at the NIH website.